| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acknowledgement
|
|
|
|
33 |
S3 |
p. viii
|
article
|
| 2 |
Editorial Board
|
|
|
|
33 |
S3 |
p. i
|
article
|
| 3 |
Journal Information
|
|
|
|
33 |
S3 |
p. ii
|
article
|
| 4 |
LBA2 Assessment of Ki67 and FOXC1-based response predictor tracking proliferation and plasticity as a complementary diagnostic for neoadjuvant olaparib+paclitaxel+durvalumab in primary triple-negative breast cancer: Retrospective analysis of the I-SPY2 trial
|
Ray, P.S.
|
|
|
33 |
S3 |
p. S123
|
article
|
| 5 |
LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
|
Prat, A.
|
|
|
33 |
S3 |
p. S164
|
article
|
| 6 |
LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
|
Mosele, M.F.
|
|
|
33 |
S3 |
p. S123
|
article
|
| 7 |
LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)
|
Neven, P.
|
|
|
33 |
S3 |
p. S194
|
article
|
| 8 |
59MO Adjuvant abemaciclib combined with endocrine therapy (ET): Efficacy results in monarchE cohort 1
|
Toi, M.
|
|
|
33 |
S3 |
p. S149
|
article
|
| 9 |
167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
|
De La Motte Rouge, T.
|
|
|
33 |
S3 |
p. S200
|
article
|
| 10 |
3MO Association of the research-based HER2DX signatures with survival in early-stage triple-negative breast cancer (eTNBC)
|
Conte, B.
|
|
|
33 |
S3 |
p. S124-S125
|
article
|
| 11 |
166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
|
Schmid, P.
|
|
|
33 |
S3 |
p. S199
|
article
|
| 12 |
2MO Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients
|
Di Cosimo, S.
|
|
|
33 |
S3 |
p. S124
|
article
|
| 13 |
92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8
|
Jerusalem, G.
|
|
|
33 |
S3 |
p. S165-S166
|
article
|
| 14 |
93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
|
Gebhart, G.
|
|
|
33 |
S3 |
p. S166
|
article
|
| 15 |
60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B
|
Furlanetto, J.
|
|
|
33 |
S3 |
p. S149-S150
|
article
|
| 16 |
1MO Prognostic and biologic significance of HER2-low expression in early breast cancer
|
Tarantino, P.
|
|
|
33 |
S3 |
p. S124
|
article
|
| 17 |
91MO Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial
|
Murray, N.
|
|
|
33 |
S3 |
p. S164-S165
|
article
|
| 18 |
165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
|
Bartsch, R.
|
|
|
33 |
S3 |
p. S198
|
article
|
| 19 |
Notice and Disclaimer
|
|
|
|
33 |
S3 |
p. iii
|
article
|
| 20 |
164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355
|
Cescon, D.W.
|
|
|
33 |
S3 |
p. S197-S198
|
article
|
| 21 |
163O Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
|
Curigliano, G.
|
|
|
33 |
S3 |
p. S196-S197
|
article
|
| 22 |
162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
|
Hamilton, E.P.
|
|
|
33 |
S3 |
p. S196
|
article
|
| 23 |
58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
|
Marmé, F.
|
|
|
33 |
S3 |
p. S148-S149
|
article
|
| 24 |
161O VIOLETTE: Randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)
|
Tutt, A.
|
|
|
33 |
S3 |
p. S194-S195
|
article
|
| 25 |
202P Abemaciclib in HR+/Her2- metastatic breast cancer patients after previous progression on palbociclib or ribociclib: Clinical experience in a tertiary hospital in Madrid, Spain
|
De Luna Aguilar, A.
|
|
|
33 |
S3 |
p. S219-S220
|
article
|
| 26 |
28P ACLY-mediated breast tumorigenesis is driven by immune escape via PD-L1 signaling
|
Hegde, M.
|
|
|
33 |
S3 |
p. S136
|
article
|
| 27 |
212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?
|
Javadinia, S.A.
|
|
|
33 |
S3 |
p. S225
|
article
|
| 28 |
121P Acute skin toxicity after conservative surgery for breast cancer: Impact of radiotherapy fractionation
|
Trigui, R.
|
|
|
33 |
S3 |
p. S179
|
article
|
| 29 |
224P Adherence to adjuvant hormonal therapy in patients with localized breast cancer
|
Voutsadakis, I.
|
|
|
33 |
S3 |
p. S228
|
article
|
| 30 |
230P A digital therapeutic intervention for breast cancer patients during active treatment: A feasibility study
|
Thorvardardottir, G.E.
|
|
|
33 |
S3 |
p. S230
|
article
|
| 31 |
157P Adoptive cell therapy with cytokine-induced killer cells retargeted with immunotools against HER-2-expressing breast cancer
|
Perpinello, S.
|
|
|
33 |
S3 |
p. S192
|
article
|
| 32 |
180P A doubling in overall survival of patients with de novo HER2+ advanced breast cancer in the Netherlands
|
Geurts, S.M.E.
|
|
|
33 |
S3 |
p. S210
|
article
|
| 33 |
199P Advanced breast cancer patient involvement in the evaluation of an available online exercise program for use in a future clinical trial
|
Harper-Wynne, C.
|
|
|
33 |
S3 |
p. S219
|
article
|
| 34 |
175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
|
Cardoso, F.
|
|
|
33 |
S3 |
p. S206-S207
|
article
|
| 35 |
245P A multidisciplinary virtual intervention to address information needs of Mexican patients with breast cancer
|
López-Bejarano, R.L.
|
|
|
33 |
S3 |
p. S235
|
article
|
| 36 |
215P Analysis of factors impacting the outcome in young breast cancers in low middle-income countries
|
Iyer, P.
|
|
|
33 |
S3 |
p. S225-S226
|
article
|
| 37 |
49P Analysis of HER2-low carcinomas and PAM50 signature in an early-stage breast cancer cohort
|
Sanchez Bayona, R.
|
|
|
33 |
S3 |
p. S143-S144
|
article
|
| 38 |
193P A national retrospective multicentre audit of long-term trastuzumab use in metastatic breast cancer: Breast Cancer Trainees Collaborative Group
|
McCartney, T.
|
|
|
33 |
S3 |
p. S216
|
article
|
| 39 |
8P An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
|
Blaye, C.
|
|
|
33 |
S3 |
p. S127
|
article
|
| 40 |
110P An in-depth analysis of pathology results of surgical specimen and biopsies performed after NST in an attempt to identify patients with pCR: Time to reconsider the omission of surgery?
|
van Hemert, A.K.E.
|
|
|
33 |
S3 |
p. S175
|
article
|
| 41 |
77P A real-world population study in early breast cancer to identify patient characteristics, treatment and outcomes in Scotland
|
Hall, P.
|
|
|
33 |
S3 |
p. S158
|
article
|
| 42 |
186P A real-world study on prevalence of and outcomes related to brain metastases among patients with HER2-positive metastatic breast cancer (mBC)
|
Collins, J.
|
|
|
33 |
S3 |
p. S213
|
article
|
| 43 |
155P A retrospective analysis of women at high risk of breast cancer: A single centre surveillance experience
|
Mammone, G.
|
|
|
33 |
S3 |
p. S191
|
article
|
| 44 |
71P Aromatase inhibitors and fracture prevention: Is our current approach correct?
|
Mirza, A.
|
|
|
33 |
S3 |
p. S155
|
article
|
| 45 |
16P Assessing early changes in plasma HER2 levels is useful for predicting therapeutic response in advanced breast cancer: A multicenter, prospective, noninterventional clinical study
|
Kang, Y-K.
|
|
|
33 |
S3 |
p. S130
|
article
|
| 46 |
178P Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: A real-world (RW) multi-country survey
|
Cardoso, F.
|
|
|
33 |
S3 |
p. S208-S209
|
article
|
| 47 |
211P Assessment of the financial toxicity after oncological treatment in patients with breast cancer in private oncological reference institutions in Brazil
|
Vieira, A.C.
|
|
|
33 |
S3 |
p. S224
|
article
|
| 48 |
27P Association between CD8+ tumor infiltrating lymphocytes and the clinical outcome of patients with operable breast cancer treated with adjuvant dose-dense chemotherapy: A 10-year follow up report of a Hellenic Cooperative Oncology Group observational study
|
Spathas, N.
|
|
|
33 |
S3 |
p. S136
|
article
|
| 49 |
228P Association between chemotherapy toxicities and financial problems in the first three cycles of chemotherapy breast cancer patients
|
Kurniawan, A.
|
|
|
33 |
S3 |
p. S230
|
article
|
| 50 |
149P Associations between the 313-SNP polygenic risk score and breast cancer risk in women from Crete
|
Yiangou, K.
|
|
|
33 |
S3 |
p. S189
|
article
|
| 51 |
140P A study on assessment of barriers to genetic counselling and testing among breast and ovarian cancer patients in a tertiary referral hospital in India
|
Siripurapu, I.
|
|
|
33 |
S3 |
p. S186
|
article
|
| 52 |
113P Axillary lymph node management in early breast cancer patients with positive sentinel lymph node: A systematic review and meta-analysis of randomized trials
|
Ruelle, T.
|
|
|
33 |
S3 |
p. S176
|
article
|
| 53 |
114P Axillary management in elderly women (≥70 years) with breast cancer: 10-years follow-up
|
Girardi, A.
|
|
|
33 |
S3 |
p. S176-S177
|
article
|
| 54 |
248P Axillary nodal involvement (ANI) predictive model by primary histopathological features in invasive breast cancer (IBC): A real-world analysis of 1,400 cases
|
Cutuli, B.
|
|
|
33 |
S3 |
p. S236
|
article
|
| 55 |
120P AXSANA (AXillary Surgery After NeoAdjuvant Treatment) EUBREAST-3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)
|
Ruf, F.
|
|
|
33 |
S3 |
p. S178-S179
|
article
|
| 56 |
22P Biobanking in breast cancer: 10 years of practice at the European Institute of Oncology
|
Viale, G.
|
|
|
33 |
S3 |
p. S132-S133
|
article
|
| 57 |
171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer
|
Marmé, F.
|
|
|
33 |
S3 |
p. S203-S204
|
article
|
| 58 |
231P Body image dissatisfaction among Tunisian young women in post treatment of breast cancer
|
Zanzouri, R.
|
|
|
33 |
S3 |
p. S231
|
article
|
| 59 |
138P Bone mineral density and risk of breast cancer: A cohort study and Mendelian randomization analysis
|
Zhang, Y.
|
|
|
33 |
S3 |
p. S185
|
article
|
| 60 |
219P Bone mineral density screening and monitoring in early breast cancer patients treated with aromatase inhibitors
|
Gilani, S.
|
|
|
33 |
S3 |
p. S227
|
article
|
| 61 |
50P Brain 18-FDG-PET patterns in early breast cancer subtypes: Relationship with headache
|
De Sanctis, R.
|
|
|
33 |
S3 |
p. S144
|
article
|
| 62 |
78P Breast cancer hypofractionated radiotherapy and its implications
|
Acharya, S.
|
|
|
33 |
S3 |
p. S158
|
article
|
| 63 |
147P Breast cancer in women with germline pathogenic variants: Frequency, clinical behavior, and outcomes of a consecutive series of patients from Spain
|
Rodriguez Hernandez, A.
|
|
|
33 |
S3 |
p. S188
|
article
|
| 64 |
233P Breast cancer organoids mimic disease heterogeneity, allow high-throughput drug screening and show correlation with clinical response
|
Dantes, Z.
|
|
|
33 |
S3 |
p. S232
|
article
|
| 65 |
139P Breast cancer risk estimation (CanRisk tool) and perception in unaffected women with family history of breast cancer
|
Ramon y Cajal, T.
|
|
|
33 |
S3 |
p. S185-S186
|
article
|
| 66 |
146P Breast cancer screening in Libya: Results of the first pilot study
|
Attia, A.A.
|
|
|
33 |
S3 |
p. S188
|
article
|
| 67 |
44P Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas
|
Kiladze, I.Z.
|
|
|
33 |
S3 |
p. S142
|
article
|
| 68 |
238P Budget impact analysis for the health care package by using MammaPrint in Belgium
|
De Lameillieure, K.
|
|
|
33 |
S3 |
p. S233
|
article
|
| 69 |
226P Cancer supportive care model in a developing country: An online delivery program
|
Bapsy, P.P.P.
|
|
|
33 |
S3 |
p. S229
|
article
|
| 70 |
118P CD146 interaction with integrin β1 activates LATS1-YAP signaling and provokes the radiation-resistance in breast cancer cells
|
Yuanke, L.
|
|
|
33 |
S3 |
p. S177-S178
|
article
|
| 71 |
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches
|
Parola, S.
|
|
|
33 |
S3 |
p. S172-S173
|
article
|
| 72 |
198P Cerebrospinal fluid immune cell profiling in patients with metastatic breast cancer and leptomeningeal disease
|
Huppert, L.A.
|
|
|
33 |
S3 |
p. S218
|
article
|
| 73 |
86P Change in dietary habits does not affect body composition in early breast cancer patients treated with aromatase inhibitor
|
Laini, L.
|
|
|
33 |
S3 |
p. S161
|
article
|
| 74 |
30P Circulating 27-hydroxycholesterol, 25-hydroxycholesterol, and breast cancer prognosis
|
Decker, N.
|
|
|
33 |
S3 |
p. S137
|
article
|
| 75 |
82P Clinical application of a genomic tool for decision support in breast cancer patients in Scotland
|
Peters, A.L.
|
|
|
33 |
S3 |
p. S159
|
article
|
| 76 |
174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis
|
Balmana, J.
|
|
|
33 |
S3 |
p. S205-S206
|
article
|
| 77 |
81P Clinical experience with EndoPredict test: Building a clinicopathological model predictive of genomic test result
|
Di Lascio, S.
|
|
|
33 |
S3 |
p. S159
|
article
|
| 78 |
209P Clinically relevant impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: A population-based study
|
Engvall, K.
|
|
|
33 |
S3 |
p. S224
|
article
|
| 79 |
13P Clinicopathological and prognostic significance of tertiary lymphoid structures in breast cancer: A systemic review and meta-analysis
|
Wang, B.
|
|
|
33 |
S3 |
p. S129
|
article
|
| 80 |
17P Clinicopathological and transcriptomic characterization of luminal HER2-enriched breast cancer
|
Hohmann, L.
|
|
|
33 |
S3 |
p. S130-S131
|
article
|
| 81 |
67P Clinicopathologic features of breast cancer patients eligible for adjuvant abemaciclib
|
Tarantino, P.
|
|
|
33 |
S3 |
p. S152-S153
|
article
|
| 82 |
46P Co-expression of GR with PR isoforms is associated with differential prognosis in estrogen receptor-positive breast cancer
|
Nimbalkar, V.P.
|
|
|
33 |
S3 |
p. S142
|
article
|
| 83 |
18P Comparative genomic profiling of primary and locally recurrent luminal breast cancers (BC)
|
Rassy, E.
|
|
|
33 |
S3 |
p. S131
|
article
|
| 84 |
64P Concomitant discontinuation of cardiovascular therapy and adjuvant hormone therapy in breast cancer patients
|
Zeng, E.
|
|
|
33 |
S3 |
p. S152
|
article
|
| 85 |
40P Connexin43 as double therapeutic target in triple-negative breast cancer: Role in tumour progression and antitumour immune response
|
Rodriguez-Candela Mateos, M.
|
|
|
33 |
S3 |
p. S140
|
article
|
| 86 |
85P Correlation between nCOUNTER PAM-50 assay and three IHC-based surrogate intrinsic breast cancer subtype classifiers: A real-world study
|
Martín, M.
|
|
|
33 |
S3 |
p. S160-S161
|
article
|
| 87 |
99P Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States
|
Fasching, P.A.
|
|
|
33 |
S3 |
p. S170-S171
|
article
|
| 88 |
240P COVID-19 pandemic impact on diagnosis and management of breast cancer in Northern Portugal
|
Teixeira-Pinto, R.
|
|
|
33 |
S3 |
p. S234
|
article
|
| 89 |
203P Curative treatment outcomes in metaplastic breast cancer
|
Yit, L.F.N.
|
|
|
33 |
S3 |
p. S220
|
article
|
| 90 |
197P Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: A modified Delphi study
|
Karihtala, P.
|
|
|
33 |
S3 |
p. S218
|
article
|
| 91 |
125P De-escalation of breast cancer surgery after neoadjuvant systemic therapy in cCR/pCR patients confirmed by vacuum-assisted biopsy (VAB) and SLNB: A first report of the prospective non-randomized trial results
|
Krivorotko, P.
|
|
|
33 |
S3 |
p. S180
|
article
|
| 92 |
143P Demographics of breast cancer and non-malignant breast lesions in Western India: A study of 8000 breast pathologies
|
Agarwal, N.K.
|
|
|
33 |
S3 |
p. S187
|
article
|
| 93 |
148P Descriptive study of mutation status and clinical phenotype in breast cancer patients of South Catalonia
|
Cochs, A.
|
|
|
33 |
S3 |
p. S188-S189
|
article
|
| 94 |
7P Development and validation of a deep learning RNA modification model predict disease-free survival in patients with breast cancer
|
Yu, Y.
|
|
|
33 |
S3 |
p. S126-S127
|
article
|
| 95 |
227P Development of a novel free-to-use software for upper limb volume assessment in breast cancer related lymphedema: Integrating an augmented reality tool in the complex management of breast cancer survivors
|
Lippi, L.
|
|
|
33 |
S3 |
p. S229
|
article
|
| 96 |
187P Development of a patient-centered core outcome set for metastatic breast cancer
|
de Ligt, K.M.
|
|
|
33 |
S3 |
p. S213-S214
|
article
|
| 97 |
54P Development of a prognostic test for breast cancer recurrence using a highly efficient molecular profiling platform
|
Capewell, P.
|
|
|
33 |
S3 |
p. S145
|
article
|
| 98 |
136P Development of breast cancer risk prediction models using the UK Biobank dataset
|
Alajmi, K.
|
|
|
33 |
S3 |
p. S184-S185
|
article
|
| 99 |
220P Distant disease-free survival according to different subtypes in young breast cancer patients (YBCP)
|
Cantos, B.
|
|
|
33 |
S3 |
p. S227
|
article
|
| 100 |
246P DNA repair protein RAD51 homolog 1 (RAD51), a potential prognostic biomarker and target for breast cancer
|
Tang, Y-Q.
|
|
|
33 |
S3 |
p. S235-S236
|
article
|
| 101 |
130P Dosimetric evaluation of continuous positive airway pressure with deep inspiratory breath hold for left sided breast cancer
|
Singh, P.
|
|
|
33 |
S3 |
p. S182
|
article
|
| 102 |
122P Dual plane intraoperative digital radiography in breast-conserving surgery
|
Maksimov, N.
|
|
|
33 |
S3 |
p. S179
|
article
|
| 103 |
43P Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy
|
Wu, Q.
|
|
|
33 |
S3 |
p. S141
|
article
|
| 104 |
73P Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the CONTROL trial
|
Chan, A.
|
|
|
33 |
S3 |
p. S156
|
article
|
| 105 |
129P Effect of intra-operative and post operative topical tranexamic acid on the duration and the volume of the intra-operative drain in patients undergoing axillary lymph node dissection for breast cancer: A randomized controlled trial
|
Irrinki, R.N.N.S.
|
|
|
33 |
S3 |
p. S181-S182
|
article
|
| 106 |
183P Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Initial results from a phase II study
|
Makharadze, T.
|
|
|
33 |
S3 |
p. S212
|
article
|
| 107 |
63P Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- high-risk early breast cancer
|
Paluch-Shimon, S.
|
|
|
33 |
S3 |
p. S151
|
article
|
| 108 |
184P Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials
|
Ergün, Y.
|
|
|
33 |
S3 |
p. S212
|
article
|
| 109 |
181P Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from a pooled analysis of two phase III studies
|
Twelves, C.J.
|
|
|
33 |
S3 |
p. S210-S211
|
article
|
| 110 |
229P Efficiency of SARS-CoV-2 vaccines in breast cancer patients: Single institutional experience from Institute for Oncology and Radiology of Serbia (IORS)
|
Djurmez, O.I.
|
|
|
33 |
S3 |
p. S230
|
article
|
| 111 |
42P Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial
|
Gampenrieder, S.P.
|
|
|
33 |
S3 |
p. S141
|
article
|
| 112 |
173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2
|
Lu, J.
|
|
|
33 |
S3 |
p. S204-S205
|
article
|
| 113 |
87P EPClin vs OncotypeDx in invasive lobular cancer (ILC)
|
Leao, I.
|
|
|
33 |
S3 |
p. S161
|
article
|
| 114 |
234P Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests
|
Schuler, E.
|
|
|
33 |
S3 |
p. S232
|
article
|
| 115 |
35P European consensus on the utility of breast cancer multigene signatures in routine clinical practice: PROCURE project final results
|
Curigliano, G.
|
|
|
33 |
S3 |
p. S138-S139
|
article
|
| 116 |
65P Evaluation of survival outcome of adjuvant chemoradiotherapy compared to other treatment modalities stratified by tumor size in T1N0M0 triple-negative breast cancer
|
Ellaithy, A.
|
|
|
33 |
S3 |
p. S152
|
article
|
| 117 |
26P Evaluation of tumor-infiltrating lymphocytes on matched baseline and residual disease samples of triple-negative breast cancer patients treated with anthracycline-taxane based neoadjuvant chemotherapy with or without carboplatin
|
Miglietta, F.
|
|
|
33 |
S3 |
p. S135-S136
|
article
|
| 118 |
5P Exploratory biomarker analysis from neoadjuvant atezolizumab, pertuzumab, trastuzumab plus docetaxel (NEO-PATH) in HER2+ early breast cancer
|
Ahn, H.K.
|
|
|
33 |
S3 |
p. S125-S126
|
article
|
| 119 |
241P Factors associated with delayed presentation of breast cancer among South Asian women (Nepal)
|
Shahi, A.
|
|
|
33 |
S3 |
p. S234
|
article
|
| 120 |
70P Factors influencing patient treatment decisions in early breast cancer (eBC): Discrete choice experiment (DCE) findings
|
Gennari, A.
|
|
|
33 |
S3 |
p. S154-S155
|
article
|
| 121 |
218P Fear of cancer recurrence in long-term post-menopausal breast cancer survivors
|
Bouhnik, A-D.
|
|
|
33 |
S3 |
p. S226-S227
|
article
|
| 122 |
196P Final analysis of PUFFIN: A phase III, randomised double-blind, placebo (Pla)-controlled study of pertuzumab, trastuzumab and docetaxel (PHD) for Chinese patients (pts) with previously untreated HER2-positive locally recurrent or metastatic breast cancer (LR/MBC)
|
Xu, B.
|
|
|
33 |
S3 |
p. S217-S218
|
article
|
| 123 |
88P Genetic platforms in hormone receptor (HR)+ early breast cancer (eBC): Could logistic regression models be used instead?
|
Lopez Paradis, A.
|
|
|
33 |
S3 |
p. S161-S162
|
article
|
| 124 |
97P Genomic bases of endocrine sensitivity in triple-positive early breast cancer: A translational analysis of the PerELISA trial
|
Griguolo, G.
|
|
|
33 |
S3 |
p. S169
|
article
|
| 125 |
115P Geriatric breast cancer: Does age matter?
|
Surya, T.S.H.V.
|
|
|
33 |
S3 |
p. S177
|
article
|
| 126 |
14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO
|
Teng, N.
|
|
|
33 |
S3 |
p. S129-S130
|
article
|
| 127 |
104P HELENA: Study of HER2-low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
|
Cherifi, F.
|
|
|
33 |
S3 |
p. S172
|
article
|
| 128 |
53P ‘HER2-LOW’ breast cancer brain metastases: An opportunity for targeted systemic therapies in a high-need patient population
|
Chehade, R.
|
|
|
33 |
S3 |
p. S145
|
article
|
| 129 |
76P How to explain current reluctance against therapeutic de-escalation: Results of the exploratory qualitative phase of the mixed method research program CARTE therapy in older women with early breast cancer in France
|
Bendiane, M.K.
|
|
|
33 |
S3 |
p. S157-S158
|
article
|
| 130 |
131P Immediate breast reconstruction in patients with BRCA mutation and breast cancer: Our approach
|
Ventruba, T.
|
|
|
33 |
S3 |
p. S182
|
article
|
| 131 |
47P Immune tumor microenvironment and markers of apoptosis in breast cancer in carriers of hereditary mutations in the BRCA1 gene
|
Stukan, A.I.
|
|
|
33 |
S3 |
p. S142-S143
|
article
|
| 132 |
107P Impact of COVID-19 pandemic on breast cancer neoadjuvant therapy: A retrospective institutional analysis
|
Baptista Freitas, M.C.
|
|
|
33 |
S3 |
p. S173
|
article
|
| 133 |
66P Impact of MAF selection of patients for adjuvant bisphosphonate therapy and comparison with current clinical guidance
|
Coleman, R.E.
|
|
|
33 |
S3 |
p. S152
|
article
|
| 134 |
119P Impact of magnetic resonance imaging in the surgical treatment of early breast cancer in two private cancer care centers in Lima, Peru
|
Aldecoa Bedoya, F.
|
|
|
33 |
S3 |
p. S178
|
article
|
| 135 |
225P Impact of potential drug-drug interactions (PDDI) on adherence to endocrine therapy (ET) among patients with breast cancer (BC) in the Health Improvement Network (THIN)
|
Rassy, E.
|
|
|
33 |
S3 |
p. S228-S229
|
article
|
| 136 |
124P Impact of regional lymph node hypofractionated radiotherapy on acute skin toxicity in patients with node-positive breast cancer
|
Ben Amor, R.
|
|
|
33 |
S3 |
p. S180
|
article
|
| 137 |
137P Impact of staffing a breast cancer screening clinic with clinical officers at a public referral center in Western Kenya
|
Jepkirui, S.
|
|
|
33 |
S3 |
p. S185
|
article
|
| 138 |
69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial
|
Maurer, C.
|
|
|
33 |
S3 |
p. S154
|
article
|
| 139 |
223P Implementing an exercise oncology program for breast cancer patients in Brazil: The Maple Tree Cancer Alliance experience
|
Francisco, A.
|
|
|
33 |
S3 |
p. S228
|
article
|
| 140 |
194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: Single center experience
|
Keskinkılıç, M.
|
|
|
33 |
S3 |
p. S216
|
article
|
| 141 |
200P Increase of vertebral fractures in patients with metastatic breast cancer treated with endocrine therapy combined with CDK 4/6 inhibitor
|
Lorini, L.
|
|
|
33 |
S3 |
p. S219
|
article
|
| 142 |
15P Integration of whole genome data with machine learning technology in breast cancer subtyping
|
Majer-Burman, W.
|
|
|
33 |
S3 |
p. S130
|
article
|
| 143 |
75P Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC)
|
Harbeck, N.
|
|
|
33 |
S3 |
p. S157
|
article
|
| 144 |
24P Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome
|
Sinn, B.V.
|
|
|
33 |
S3 |
p. S133-S134
|
article
|
| 145 |
23P In vivo multi-dimensional CRISPR screens identify LGALS2 as an immunotherapy target in triple-negative breast cancer
|
Ji, P.
|
|
|
33 |
S3 |
p. S133
|
article
|
| 146 |
222P Is quality of life (QoL) during chemotherapy affected by body composition?
|
Pavlovic Mavic, M.
|
|
|
33 |
S3 |
p. S228
|
article
|
| 147 |
4P Longitudinal proteogenomic profiling reveals therapeutic vulnerabilities of immunometabolism in breast cancer
|
Wang, K.
|
|
|
33 |
S3 |
p. S125
|
article
|
| 148 |
185P Long-term efficacy of trastuzumab biosimilar CT-P6 in patients with HER2-positive early breast cancer: 6-year survival analysis of phase III study results
|
Stebbing, J.
|
|
|
33 |
S3 |
p. S212-S213
|
article
|
| 149 |
172P Long-term follow-up of randomized controlled trial (RCT) of locoregional treatment versus not of the primary tumour in de-novo metastatic breast cancer
|
Nair, N.S.
|
|
|
33 |
S3 |
p. S204
|
article
|
| 150 |
102P Long-term prediction of clinical outcomes by the 21-gene test in HR+ HER2- breast cancer patients with residual disease after neoadjuvant chemotherapy
|
Peg, V.
|
|
|
33 |
S3 |
p. S171-S172
|
article
|
| 151 |
9P Long term recurrence risk predictions by CanAssist breast in a sub-cohort of TEAM trial
|
Bakre, M.
|
|
|
33 |
S3 |
p. S127
|
article
|
| 152 |
170P Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry
|
Riecke, K.
|
|
|
33 |
S3 |
p. S202-S203
|
article
|
| 153 |
177P Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)
|
Gampenrieder, S.P.
|
|
|
33 |
S3 |
p. S208
|
article
|
| 154 |
56P Lymph node germinal centres and B cell responses in triple-negative breast cancer
|
Alberts, E.
|
|
|
33 |
S3 |
p. S146
|
article
|
| 155 |
217P Maintenance of physical activity after exercise interventions: A systematic review and meta-analysis
|
Goldschmidt, S.
|
|
|
33 |
S3 |
p. S226
|
article
|
| 156 |
74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective
|
Jackisch, C.
|
|
|
33 |
S3 |
p. S156-S157
|
article
|
| 157 |
21P Metabolomic profiling and response to neoadjuvant therapy in operable breast cancer
|
Gennari, A.
|
|
|
33 |
S3 |
p. S132
|
article
|
| 158 |
201P Metastatic and survival characteristics of de novo versus relapsed breast cancer in females aged>35-years-old: A nationwide multicenter study based on hospital population
|
Zhang, J.
|
|
|
33 |
S3 |
p. S219
|
article
|
| 159 |
150P Molecular characteristics of breast cancer patients subjected to screening for germline predisposition in a population-based observational study
|
Staaf, J.
|
|
|
33 |
S3 |
p. S189
|
article
|
| 160 |
141P Molecular landscape of hereditary breast cancer in Ukrainian women
|
Kozakov, D.
|
|
|
33 |
S3 |
p. S186
|
article
|
| 161 |
55P Morphological changes and regulation of hormone receptor-related proteins in breast cancer patients with higher levels of progesterone receptor A than B treated with mifepristone
|
Saldain, L.
|
|
|
33 |
S3 |
p. S145-S146
|
article
|
| 162 |
142P Multidimensional impact of breast cancer screening: Results from a real-world French cohort
|
Cutuli, B.
|
|
|
33 |
S3 |
p. S186-S187
|
article
|
| 163 |
98P Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: Results of the safety run-in phase
|
De Caluwe, A.
|
|
|
33 |
S3 |
p. S170
|
article
|
| 164 |
32P Neutrophil to lymphocyte ratio (NLR) as a surrogate clinical marker for Ki-67 in breast cancer
|
Arora, R.
|
|
|
33 |
S3 |
p. S137
|
article
|
| 165 |
51P Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity
|
Peterson, J.
|
|
|
33 |
S3 |
p. S144
|
article
|
| 166 |
214P Obstetric complications at time of delivery amongst breast cancer survivors: A population-based cohort study
|
Kaidar-Person, O.
|
|
|
33 |
S3 |
p. S225
|
article
|
| 167 |
117P Oncological outcomes of chest wall perforator flap reconstruction in breast cancer
|
Gowda, M.
|
|
|
33 |
S3 |
p. S177
|
article
|
| 168 |
62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials
|
Martin Jimenez, M.
|
|
|
33 |
S3 |
p. S150-S151
|
article
|
| 169 |
100P Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort
|
Bajpai, J.
|
|
|
33 |
S3 |
p. S171
|
article
|
| 170 |
169P Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis
|
Rugo, H.S.
|
|
|
33 |
S3 |
p. S202
|
article
|
| 171 |
123P Paget’s disease of the breast: Our 20-year experience
|
Scardina, L.
|
|
|
33 |
S3 |
p. S179-S180
|
article
|
| 172 |
190P Palbociclib treatment in pre/perimenopausal women with advanced/metastatic breast cancer (ABC/mBC): Real-world patient characteristics, treatment patterns, and outcomes data from POLARIS
|
Karuturi, M.
|
|
|
33 |
S3 |
p. S215
|
article
|
| 173 |
96P PAM50-based ROR indexes as a tool to individualize the use of neoadjuvant endocrine therapy in ER+/HER2- breast cancer
|
Lopez Velazco, J.I.
|
|
|
33 |
S3 |
p. S168-S169
|
article
|
| 174 |
95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study
|
Pascual, T.
|
|
|
33 |
S3 |
p. S168
|
article
|
| 175 |
108P Pathologic nodal positivity in patients with cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy
|
Martinez Saez, O.
|
|
|
33 |
S3 |
p. S174
|
article
|
| 176 |
94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)
|
Reinisch, M.
|
|
|
33 |
S3 |
p. S166-S167
|
article
|
| 177 |
112P Patients’ knowledge about ductal carcinoma in situ
|
Engelhardt, E.G.
|
|
|
33 |
S3 |
p. S176
|
article
|
| 178 |
242P Patterns of management of positive sentinel lymph nodes in breast cancer patients after the American College of Surgeons Oncology Group Z0011 trial: A retrospective cohort
|
El Charif, M.H.
|
|
|
33 |
S3 |
p. S234-S235
|
article
|
| 179 |
151P Personalized approach to mammography screening during the COVID pandemic: How to make up for lost time without losing effectiveness
|
Giovanardi, F.
|
|
|
33 |
S3 |
p. S189-S190
|
article
|
| 180 |
189P Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
|
Sathe, A.G.
|
|
|
33 |
S3 |
p. S214
|
article
|
| 181 |
213P Photobiomodulation therapy for the management of chemotherapy-induced alopecia: Preliminary results of a randomized, controlled trial
|
Lodewijckx, J.
|
|
|
33 |
S3 |
p. S225
|
article
|
| 182 |
188P Pooled analysis of two phase II randomised studies (NorBreast-231 & TEMPO Breast) evaluating weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
|
Freyer, G.
|
|
|
33 |
S3 |
p. S214
|
article
|
| 183 |
176P Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial
|
Park, Y.H.
|
|
|
33 |
S3 |
p. S207-S208
|
article
|
| 184 |
236P Predicting Oncotype DX recurrence scores using clinicopathologic features: Tennessee University Nomogram: An external validation
|
Pikabea Díaz, F.
|
|
|
33 |
S3 |
p. S233
|
article
|
| 185 |
103P Prediction of response to neoadjuvant therapy in early-stage breast cancer using a biophysical simulation platform
|
Cole, J.
|
|
|
33 |
S3 |
p. S172
|
article
|
| 186 |
158P Predictors of response to neoadjuvant checkpoint inhibition with chemotherapy in triple-negative breast cancer (TNBC): A meta-analysis of randomized control trials (RCTs)
|
Roy, A.M.
|
|
|
33 |
S3 |
p. S192
|
article
|
| 187 |
12P Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients
|
Llop-Guevara, A.
|
|
|
33 |
S3 |
p. S129
|
article
|
| 188 |
221P Primary and secondary breast sarcoma: Clinical and pathological characteristics, prognostic factors and nomograms for predicting survival
|
Fala, S.
|
|
|
33 |
S3 |
p. S227-S228
|
article
|
| 189 |
152P Prognostic impact of serum vascular endothelial growth factor and VEGF gene polymorphism (rs2010963) in breast cancer patients
|
Al Hanafy, A.M.
|
|
|
33 |
S3 |
p. S190
|
article
|
| 190 |
31P Prognostic significance of the Hounsfield unit when assessing tumors in patients with breast cancer
|
Kim, K.
|
|
|
33 |
S3 |
p. S137
|
article
|
| 191 |
72P Prognostic value of HER2/CEP17 ratio in HER2-positive early breast cancer by FISH testing
|
Zheng, F.
|
|
|
33 |
S3 |
p. S155
|
article
|
| 192 |
101P Proteome and RNA-Seq changes in breast cancer patients with higher levels of progesterone receptor A than B after mifepristone treatment
|
Elia, A.M.
|
|
|
33 |
S3 |
p. S171
|
article
|
| 193 |
159P Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1
|
Fasching, P.A.
|
|
|
33 |
S3 |
p. S192-S193
|
article
|
| 194 |
34P Quadruple-negative breast cancer (PD-L1-negative triple-negative breast cancer, TNBC): Poorer response to chemotherapy and poorer survival compared to other TNBCs: A systematic review and meta-analysis
|
Kassem, L.
|
|
|
33 |
S3 |
p. S138
|
article
|
| 195 |
191P Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis
|
Marazzi, F.
|
|
|
33 |
S3 |
p. S215
|
article
|
| 196 |
182P Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) with bone metastases: A phase II study
|
Rugo, H.S.
|
|
|
33 |
S3 |
p. S211-S212
|
article
|
| 197 |
195P REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis
|
Singer, C.F.
|
|
|
33 |
S3 |
p. S217
|
article
|
| 198 |
135P Real-time genotyping-based breast cancer risk assessment in MyPeBS, an international randomized trial in the general population comparing risk-stratified to standard breast cancer screening (BCS)
|
Delaloge, S.
|
|
|
33 |
S3 |
p. S184
|
article
|
| 199 |
11P Real-world analysis of oncotype DX recurrence score (ODX RS) indications and impact on adjuvant chemotherapy (CT) decisions: Experience from the French LISE cohort
|
Charles, C.
|
|
|
33 |
S3 |
p. S128
|
article
|
| 200 |
239P Real-world evidence of comorbidities related to prognostic factors in European breast cancer patients
|
Kosmidis, P.A.
|
|
|
33 |
S3 |
p. S233-S234
|
article
|
| 201 |
25P Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial
|
Brasó-Maristany, F.
|
|
|
33 |
S3 |
p. S134-S135
|
article
|
| 202 |
235P Resumption of menses (ROM), fertility status perception and pregnancy desire in young breast cancer survivors: A real-world data survey
|
Salas Espinoza, K.J.
|
|
|
33 |
S3 |
p. S232-S233
|
article
|
| 203 |
52P RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
|
Vallon-Christersson, J.
|
|
|
33 |
S3 |
p. S144-S145
|
article
|
| 204 |
116P Robustness evaluation of VMAT by robust optimization and manual flash approach for breast cancer radiotherapy
|
Hung, H.M.
|
|
|
33 |
S3 |
p. S177
|
article
|
| 205 |
109P Routine collection of patient-reported outcomes: Impact of breast cancer therapies on body image
|
Afshar-Bakshloo, M.
|
|
|
33 |
S3 |
p. S175
|
article
|
| 206 |
168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study
|
Hurvitz, S.A.
|
|
|
33 |
S3 |
p. S200-S201
|
article
|
| 207 |
154P Screening of breast cancer: Clinical and biological profile of Tunisian women
|
Zouari, S.
|
|
|
33 |
S3 |
p. S190
|
article
|
| 208 |
127P Sentinel lymph node biopsy in older patients with breast cancer: Which subset can be omitted?
|
Grand, M.
|
|
|
33 |
S3 |
p. S181
|
article
|
| 209 |
111P Sentinel lymph node biopsy in post-neoadjuvant chemotherapy breast cancer patients using combination of fluorescein and blue dye versus blue dye alone: An interim analysis of a randomized controlled trial (SONAR-FB)
|
Rajendar, B.
|
|
|
33 |
S3 |
p. S175
|
article
|
| 210 |
84P Serum 25-hydroxyvitamin D and cancer-related fatigue: Associations and effects on health-related quality of life in breast cancer survivors during adjuvant endocrine therapy
|
Santos, B.M.M.R.
|
|
|
33 |
S3 |
p. S160
|
article
|
| 211 |
249P Significance of intraoperative frozen assessment of cavity shave margins in patients undergoing breast conservation surgery: A tertiary care centre experience
|
Jain, P.
|
|
|
33 |
S3 |
p. S237
|
article
|
| 212 |
37P SLC22A17 as a novel therapeutic target for triple-negative breast cancer
|
Kunnumakkara, A.B.
|
|
|
33 |
S3 |
p. S139
|
article
|
| 213 |
216P Socio-economic burden of disease: Survivorship costs for breast cancer
|
Michaeli, J.C.
|
|
|
33 |
S3 |
p. S226
|
article
|
| 214 |
45P Spatially-resolved single-cell HER2 tumor heterogeneity captured by biophysical modeling
|
Cook, D.
|
|
|
33 |
S3 |
p. S142
|
article
|
| 215 |
106P Subsets of circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy
|
Grigoryeva, E.
|
|
|
33 |
S3 |
p. S173
|
article
|
| 216 |
10P Survival according to early ctDNA dynamics in advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i)
|
Martinez Saez, O.
|
|
|
33 |
S3 |
p. S127-S128
|
article
|
| 217 |
144P The differences in fatty acid profiles and stearoyl-CoA desaturase (SCD1) mRNA level in adipose tissue surrounding breast tumor of Iranian women with breast cancer and benign breast disease
|
Sefidabi, R.
|
|
|
33 |
S3 |
p. S187
|
article
|
| 218 |
83P The educational impact of a curriculum for oncologists on the latest developments in the use of CDK4/6 inhibitors in HR+/HER2- early and metastatic breast cancer
|
Dorkhom, N.
|
|
|
33 |
S3 |
p. S159-S160
|
article
|
| 219 |
79P The impact of trastuzumab administration patterns on the clinical outcomes of patients with early breast cancer in resource-limited settings
|
Amer, E.A.
|
|
|
33 |
S3 |
p. S158-S159
|
article
|
| 220 |
41P The impact of tumour-infiltrating lymphocyte subpopulations on pathological complete response in HER2+ breast cancer
|
Hurley, C.
|
|
|
33 |
S3 |
p. S141
|
article
|
| 221 |
20P The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis
|
Giannoudis, A.
|
|
|
33 |
S3 |
p. S132
|
article
|
| 222 |
244P The incidence of infusion related reactions with trastuzumab-emtansine
|
Begum, P.
|
|
|
33 |
S3 |
p. S235
|
article
|
| 223 |
243P The landscape of RUNX1 mutations in breast cancer and its therapeutic potential
|
Ariffin, N.S.
|
|
|
33 |
S3 |
p. S235
|
article
|
| 224 |
48P T-helper cell-driven immune response as an effect for seroma formation (SF) after mastectomy (ME) in breast cancer (BC) (SerMa pilot EUBREAST 5)
|
Ditsch, N.
|
|
|
33 |
S3 |
p. S143
|
article
|
| 225 |
29P The molecular landscape of breast mucoepidermoid carcinoma
|
Fusco, N.
|
|
|
33 |
S3 |
p. S136-S137
|
article
|
| 226 |
33P The multi-switching activity of circulatory neutrophils in patients with early breast cancer
|
Ramessur, A.
|
|
|
33 |
S3 |
p. S137-S138
|
article
|
| 227 |
6P The oncolytic virus pelareorep primes the tumor microenvironment for checkpoint blockade therapy in early breast cancer patients: Results from AWARE-1 study
|
Gavila Gregori, J.
|
|
|
33 |
S3 |
p. S126
|
article
|
| 228 |
153P The role of screening in the timely diagnosis of breast cancer in the COVID-19 pandemic context
|
Kaidarova, D.
|
|
|
33 |
S3 |
p. S190
|
article
|
| 229 |
128P The role of volumetric modulated arc therapy in left breast cancer
|
Cheung, E.Y.W.
|
|
|
33 |
S3 |
p. S181
|
article
|
| 230 |
179P Time trends in overall survival and systemic therapy in patients with HR+/HER2- advanced breast cancer: A study of the SONABRE registry
|
Meegdes, M.
|
|
|
33 |
S3 |
p. S209
|
article
|
| 231 |
145P Trajectory of physical activity and breast cancer risk: Findings from a population-based cohort study in South Korea
|
Tran, T.T.P.
|
|
|
33 |
S3 |
p. S187-S188
|
article
|
| 232 |
192P Treatment patterns and outcomes of metastatic breast cancer (mBC) patients with HER2 IHC2+/ISH- status in the US
|
Macewan, J.
|
|
|
33 |
S3 |
p. S216
|
article
|
| 233 |
38P Tumour-infiltrating lymphocytes and correlation with prognostic signature scores in early-stage hormone-positive, HER2-negative (ER+/HER2-) breast cancer
|
Lucas, M.W.
|
|
|
33 |
S3 |
p. S140
|
article
|
| 234 |
39P Understanding the crosstalk between micro-RNA and Wnt signaling cascade associated with the expression level of HOXB13 and SRC genes in female breast cancer
|
Khan, A.K.
|
|
|
33 |
S3 |
p. S140
|
article
|
| 235 |
247P Usage and side effects of each common aromatase inhibitor in 5 large European countries: Real-world data analysis
|
Kosmidis, P.A.
|
|
|
33 |
S3 |
p. S236
|
article
|
| 236 |
126P Usefullness of perforator flaps in breast cancer: A single-centre clinical audit from India
|
Koppiker, C.B.
|
|
|
33 |
S3 |
p. S180-S181
|
article
|
| 237 |
19P Usefulness of Hounsfield unit on computed tomography, serum neutrophil to lymphocyte ratio, and their combination as prognostic factor in patients with breast cancer
|
Han, A.
|
|
|
33 |
S3 |
p. S131-S132
|
article
|
| 238 |
133P Using breast cancer risk factors of women to estimate incidence of breast cancer in their sisters
|
Mao, X.
|
|
|
33 |
S3 |
p. S184
|
article
|
| 239 |
210P Worsening of breast cancer patients’ condition: What happened during COVID-19? A meta-analysis
|
Nagy, M.
|
|
|
33 |
S3 |
p. S224
|
article
|
| 240 |
68P 20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials
|
Dar, H.A.
|
|
|
33 |
S3 |
p. S153-S154
|
article
|
| 241 |
36P Young breast cancer biology explored by NanoString BC360 panel in a formalin-fixed paraffin-embedded cohort
|
Ingebriktsen, L.M.
|
|
|
33 |
S3 |
p. S139
|
article
|
| 242 |
Society Pages
|
|
|
|
33 |
S3 |
p. vi-vii
|
article
|
| 243 |
Table of Contents
|
|
|
|
33 |
S3 |
p. v
|
article
|
| 244 |
90TiP Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)
|
Rossi, G.
|
|
|
33 |
S3 |
p. S162-S163
|
article
|
| 245 |
204TiP A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)
|
Hamilton, E.P.
|
|
|
33 |
S3 |
p. S220
|
article
|
| 246 |
160TiP A randomized controlled phase III study of bevacizumab and paclitaxel in combination with atezolizumab as a treatment for patients with locally advanced or metastatic hormone receptor-positive HER2-negative breast cancer: JCOG1919E/AMBITION study
|
Hara, F.
|
|
|
33 |
S3 |
p. S193
|
article
|
| 247 |
205TiP ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
|
Cortés Salgado, A.
|
|
|
33 |
S3 |
p. S221
|
article
|
| 248 |
156TiP BRCA-DIRECT: A randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer
|
Torr, B.
|
|
|
33 |
S3 |
p. S191
|
article
|
| 249 |
232TiP Early acupuncture treatment of vasomotor symptoms and sleep disorders in breast cancer LHRHa induced menopause: AcuFLASH Study
|
Maggiore, C.
|
|
|
33 |
S3 |
p. S231
|
article
|
| 250 |
132TiP HCB-ONC001 ELPIS TRIAL: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2-positive breast cancer with high HER2 addiction and a complete response following standard anti-HER2-based neoadjuvant therapy
|
Pascual, T.
|
|
|
33 |
S3 |
p. S182-S183
|
article
|
| 251 |
250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation
|
Lu, J.
|
|
|
33 |
S3 |
p. S223
|
article
|
| 252 |
89TiP Perceptions, attitudes, and behaviors towards the risk of disease recurrence among women with early-stage HER2+ breast cancer in Europe: The ASKHER2 survey
|
Zkik, A.
|
|
|
33 |
S3 |
p. S162
|
article
|
| 253 |
207TiP Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)
|
Dieras, V.C.
|
|
|
33 |
S3 |
p. S222
|
article
|
| 254 |
206TiP Randomized, multicenter, international phase III ARTEST study to evaluate enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic breast cancer in patients who previously received an estrogen-blocking agent and a CDK 4/6 inhibitor
|
Brufsky, A.
|
|
|
33 |
S3 |
p. S221
|
article
|
| 255 |
208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial
|
Ciruelos, E.M.
|
|
|
33 |
S3 |
p. S222-S223
|
article
|
| 256 |
57TiP SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial
|
Balmana, J.
|
|
|
33 |
S3 |
p. S146-S147
|
article
|
| 257 |
Title Page
|
|
|
|
33 |
S3 |
p. iv
|
article
|
Journal description